Primary intestinal posttransplant T-cell lymphoma

J. Michael, Stuart M. Greenstein, R. Schechner, V. Tellis, L. V. Vasovic, H. Ratech, Daniel Glicklich

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

There have been only five reported cases of primary posttransplant T-cell lymphoma. We report the first case associated with the use of sirolimus (Rapamycin, Wyeth-Ayerst, Philadelphia, PA). The patient, receiving prednisone, cyclosporine, and sirolimus treatment, developed ascites, diarrhea, and weight loss 7 months after his second renal transplant. Tissue obtained at laparotomy established the diagnosis of primary T-cell lymphoma. Latent membrane protein-1 for Epstein-Barr virus was negative, but in-site hybridization test for Epstein-Barr-encoded RNA was positive. Despite aggressive chemotherapy, the patient died 8 months posttransplant. This is the sixth reported case of primary intestinal posttransplant T-cell lymphoma, but it is the first case associated with the use of sirolimus. The incidence of posttransplant lymphoproliferative disease in patients receiving sirolimus should be studied.

Original languageEnglish (US)
Pages (from-to)2131-2132
Number of pages2
JournalTransplantation
Volume75
Issue number12
DOIs
StatePublished - Jun 27 2003

Fingerprint

T-Cell Lymphoma
Sirolimus
Prednisone
Ascites
Laparotomy
Cyclosporine
Weight Loss
Diarrhea
RNA
Transplants
Kidney
Drug Therapy
Incidence

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Michael, J., Greenstein, S. M., Schechner, R., Tellis, V., Vasovic, L. V., Ratech, H., & Glicklich, D. (2003). Primary intestinal posttransplant T-cell lymphoma. Transplantation, 75(12), 2131-2132. https://doi.org/10.1097/01.TP.0000060253.54333.F3

Primary intestinal posttransplant T-cell lymphoma. / Michael, J.; Greenstein, Stuart M.; Schechner, R.; Tellis, V.; Vasovic, L. V.; Ratech, H.; Glicklich, Daniel.

In: Transplantation, Vol. 75, No. 12, 27.06.2003, p. 2131-2132.

Research output: Contribution to journalArticle

Michael, J, Greenstein, SM, Schechner, R, Tellis, V, Vasovic, LV, Ratech, H & Glicklich, D 2003, 'Primary intestinal posttransplant T-cell lymphoma', Transplantation, vol. 75, no. 12, pp. 2131-2132. https://doi.org/10.1097/01.TP.0000060253.54333.F3
Michael J, Greenstein SM, Schechner R, Tellis V, Vasovic LV, Ratech H et al. Primary intestinal posttransplant T-cell lymphoma. Transplantation. 2003 Jun 27;75(12):2131-2132. https://doi.org/10.1097/01.TP.0000060253.54333.F3
Michael, J. ; Greenstein, Stuart M. ; Schechner, R. ; Tellis, V. ; Vasovic, L. V. ; Ratech, H. ; Glicklich, Daniel. / Primary intestinal posttransplant T-cell lymphoma. In: Transplantation. 2003 ; Vol. 75, No. 12. pp. 2131-2132.
@article{c5c25579a5024e18b8f5cc77effb3b69,
title = "Primary intestinal posttransplant T-cell lymphoma",
abstract = "There have been only five reported cases of primary posttransplant T-cell lymphoma. We report the first case associated with the use of sirolimus (Rapamycin, Wyeth-Ayerst, Philadelphia, PA). The patient, receiving prednisone, cyclosporine, and sirolimus treatment, developed ascites, diarrhea, and weight loss 7 months after his second renal transplant. Tissue obtained at laparotomy established the diagnosis of primary T-cell lymphoma. Latent membrane protein-1 for Epstein-Barr virus was negative, but in-site hybridization test for Epstein-Barr-encoded RNA was positive. Despite aggressive chemotherapy, the patient died 8 months posttransplant. This is the sixth reported case of primary intestinal posttransplant T-cell lymphoma, but it is the first case associated with the use of sirolimus. The incidence of posttransplant lymphoproliferative disease in patients receiving sirolimus should be studied.",
author = "J. Michael and Greenstein, {Stuart M.} and R. Schechner and V. Tellis and Vasovic, {L. V.} and H. Ratech and Daniel Glicklich",
year = "2003",
month = "6",
day = "27",
doi = "10.1097/01.TP.0000060253.54333.F3",
language = "English (US)",
volume = "75",
pages = "2131--2132",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Primary intestinal posttransplant T-cell lymphoma

AU - Michael, J.

AU - Greenstein, Stuart M.

AU - Schechner, R.

AU - Tellis, V.

AU - Vasovic, L. V.

AU - Ratech, H.

AU - Glicklich, Daniel

PY - 2003/6/27

Y1 - 2003/6/27

N2 - There have been only five reported cases of primary posttransplant T-cell lymphoma. We report the first case associated with the use of sirolimus (Rapamycin, Wyeth-Ayerst, Philadelphia, PA). The patient, receiving prednisone, cyclosporine, and sirolimus treatment, developed ascites, diarrhea, and weight loss 7 months after his second renal transplant. Tissue obtained at laparotomy established the diagnosis of primary T-cell lymphoma. Latent membrane protein-1 for Epstein-Barr virus was negative, but in-site hybridization test for Epstein-Barr-encoded RNA was positive. Despite aggressive chemotherapy, the patient died 8 months posttransplant. This is the sixth reported case of primary intestinal posttransplant T-cell lymphoma, but it is the first case associated with the use of sirolimus. The incidence of posttransplant lymphoproliferative disease in patients receiving sirolimus should be studied.

AB - There have been only five reported cases of primary posttransplant T-cell lymphoma. We report the first case associated with the use of sirolimus (Rapamycin, Wyeth-Ayerst, Philadelphia, PA). The patient, receiving prednisone, cyclosporine, and sirolimus treatment, developed ascites, diarrhea, and weight loss 7 months after his second renal transplant. Tissue obtained at laparotomy established the diagnosis of primary T-cell lymphoma. Latent membrane protein-1 for Epstein-Barr virus was negative, but in-site hybridization test for Epstein-Barr-encoded RNA was positive. Despite aggressive chemotherapy, the patient died 8 months posttransplant. This is the sixth reported case of primary intestinal posttransplant T-cell lymphoma, but it is the first case associated with the use of sirolimus. The incidence of posttransplant lymphoproliferative disease in patients receiving sirolimus should be studied.

UR - http://www.scopus.com/inward/record.url?scp=0038451501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038451501&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000060253.54333.F3

DO - 10.1097/01.TP.0000060253.54333.F3

M3 - Article

VL - 75

SP - 2131

EP - 2132

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -